According to China Biological, on January 9, the China National Pharmaceutical Group's Shanghai Biological Product Research Institute independently developed Class I innovative antibody-drug conjugate (ADC) SIBP-A18 received the clinical trial approval notice from the National Medical Products Administration. This product is intended for the treatment of advanced malignant solid tumors such as gastric cancer/gastroesophageal junction adenocarcinoma and pancreatic cancer.
中国生物：I类创新型抗体偶联药物SIBP-A18获批临床
China Biologics: Class I innovative antibody-drug conjugate SIBP-A18 has been approved for clinical use.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated